



Company Announcement

Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform's Ability to Modulate Multiple Key Immune Components in Autoimmune Disease

- New preclinical data indicates effect on all major components of immune system involved in autoimmune diseases
- Data presented at the 8th Antigen-Specific Immune Tolerance Drug Development Summit (ASIT) in Boston

Oslo, Norway, February 27, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new preclinical findings reinforcing the unique mechanism of action and potential of its APC-targeted immune therapy platform in treating autoimmune diseases.

Important new data show that Nykode's APC-targeted constructs increase antigen-specific regulatory T cells, which are known to downregulate an unwanted immune response, while simultaneously reducing antigen-specific effector T cells that drive inflammation. Furthermore, new data show that Nykode's APC-targeted constructs can reduce the generation of antigen-specific IgG autoantibodies, thereby shaping also the humoral component of the immune response, which is known to be involved in many autoimmune conditions. These changes suggest that the therapy works effectively through multiple arms of the antigen-specific immune system to promote its effectiveness and support its potential as a future therapy for autoimmune disorders, allergy and organ transplant rejection.

Furthermore, new data show that Nykode's APC-targeting unit is essential for the observed increased effect in alleviating disease symptoms across preclinical autoimmune models, demonstrating the versatility and efficacy of the platform.

"These novel data deepen our confidence in the underlying mechanisms of our APC-targeted therapy platform and its potential in treating conditions caused by an unwanted immune response, such as autoimmune diseases," said Agnete Fredriksen, Chief Scientific Officer and Co-founder of Nykode. "We are encouraged by the ability to measure the effect through multiple arms of the immune system, which reinforces our opportunity to build on the strength and diversity of our unique APC-technology to drive highly specific and customized immune tolerance."

Most of the data have been generated using MOG and PLP-1 antigens, which are applicable in chronic and relapsing-remitting EAE models.

Nykode remains committed to advancing its immune tolerance platform and further exploring the clinical potential of APC-targeted therapy for autoimmune diseases, allergies, and organ transplant rejection.



The poster and presentation are available on the Nykode website at <https://nykode.com/research-and-development/scientific-papers-and-presentations>.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, is being investigated in a trial with more than 10 different indications.

The Company's partnerships include a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway